This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

PALOMA-3 Trial Quality- of-life Outcomes

Confidence in a Treatment that's Setting the Standard1-3​​​​​​​​​​​​​​​​

​​​​​​​The PALOMA-3 study shows that you can offer patients efficacy without compromising QoL with IBRANCE® in combination with fulvestrant.4

Patient-reported HRQoL was a secondary outcome in the PALOMA-3 study.4​​

PALOMA-3: Global QoL in the ITT population4 

IBRANCE® + fulvestrant generally maintained global QoL (EORTC QLQ-C30); a significant deterioration was observed with fulvestrant alone (p=0.03).4

IBRANCE® + fulvestrant significantly improved emotional functioning compared with fulvestrant alone (p=0.002).4 ​​​​​​​

Adapted from Turner NC, et al. Ann Oncol 2018;29:669–680.5

IBRANCE® plus fulvestrant resulted in more favourable patient QoL scores in all areas whereas patient QoL deteriorated in patients receiving fulvestrant plus placebo.4​​​​​​​

PALOMA-3: Deterioration in Global QoL5 

A statistically significantly greater delay in time to deterioration in global QoL (EORTC QLQ-C30) was observed with IBRANCE® + fulvestrant compared with fulvestrant alone in patients with visceral metastases (p<0.001).5

A similar trend was observed in patients without visceral metastases, but it was not statistically significant.5

Global QoL in Patients Without Visceral Metastases5

Adapted from Turner NC, et al. 2018. Data cut-off October 2015.5

Global QoL in Patients With Visceral Metastases5

Adapted from Turner NC, et al. 2018. Data cut-off October 2015.5

PALOMA-3: Time to Deterioration in Pain Score4 

There was a significant decrease in pain* with IBRANCE® + fulvestrant compared with fulvestrant + placebo (−3.3 vs 2.0, p=0.0011).4

IBRANCE® plus fulvestrant significantly delayed TTD in pain symptoms compared with fulvestrant plus placebo (p<0.001).4

Adapted from Harbeck N, et al. 2016.4
*EORTC QLQ-C30 symptom dimension. In a population of pre-/peri- and postmenopausal women with HR+/HER2- advanced or metastatic breast cancer who had progressed on previous ET therapy.4

AI : Aromatase Inhibitor, CI : Confidence Interval, EORCT QLQ-C30 : European Organisation for Research and Treatment of Cancer Quality Of Life Questionnaire C30, ET : Endocrine Therapy, HR : Hazard Ratio, HR+/HER2- : Hormone Receptor‑Positive/Human Epidermal Growth Factor Receptor 2-Negative, HRQoL : Health-Related Quality of Life, ITT : Intention-To-Treat, LHRH : Luteinising Hormone-Releasing Hormone, NE : Not Estimable, NR : Not Reached, QoL : Quality of Life, SmPC : Summary of Product Characteristics, TTD : Time to Deterioration.​​​​​​​

References
  1. Cristofanilli M, et al. Lancet Oncol 2016;17:425–439.
  2. Cristofanilli M, et al. ECJ 2018;104:21-31.
  3. Turner NC, et al. N Engl J Med 2018;379:1926–1936 including supplementary appendix.
  4. ​​​​​​​Harbeck N, et al. Ann Oncol 2016;27:1047–1054.
  5. Turner NC, et al. Ann Oncol 2018;29:669–680.
PP-IBR-GBR-4358. May 2022

PALOMA-3 Trial

Clinical Trials

  • Clinical Trial results for IBRANCE®
  • IBRANCE® Clinical Trials
  • PALOMA-2 Trial

    ​​​​​​​PALOMA-3 Trial

Header

This text is for block level content. P tags can go in here too

Safety

IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management

Indication

  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?